Direct answer. The published abdominal CBL-514 program moved from an open-label dose-ranging Phase IIa study to placebo-controlled Phase II and Phase 2b studies. Across those papers, the primary questions changed from ultrasound-derived volume and response thresholds to a clinician-rated abdominal-fat scale; their percentages are not interchangeable.
Availability update (30 October 2026). Caliway states that its investigational CBL-514 is not commercially available and that it has not authorized any third party to supply, distribute, market or sell it. A third-party vial claim is not evidence of access to the developer’s clinical material or approval to sell it.
The 2022 study asked a dose-ranging question
The 2022 Phase IIa publication describes random allocation among three CBL-514 dose levels in an open-label abdominal study. It reports ultrasound-assessed changes in subcutaneous fat volume and thickness after a treatment period and 4- and 8-week follow-up visits. Because the groups received different active dose levels and there was no placebo arm, a change from baseline in this paper does not estimate the same contrast as an active-versus-placebo result. The authors describe an exploratory stage of the program, not a treatment standard.
The study’s dose and injection details belong to its controlled protocol. They must not be copied into a consumer “dosage” page or used to infer the fill of a separately offered vial. For evidence extraction, record the intervention arm, ultrasound calculation, number of participants contributing to each analysis and follow-up visit. A volume in millilitres is a measured study outcome within that design; it is not a universal expectation for a different formulation, anatomical site or person.
Record the design first
- Design: open label with randomized active dose groups.
- Measure: ultrasound-derived abdominal volume and thickness.
- Interpretation: within-study dose exploration, not placebo-adjusted efficacy.
The 2025 paper introduced a placebo-adjusted threshold
The 2025 randomized Phase II paper compared CBL-514 with placebo in adults studied for abdominal subcutaneous fat reduction. Its primary endpoint was the proportion with an ultrasound-derived volume loss of at least 150 mL. The paper reports 69.6% of CBL-514 participants meeting that threshold at 8 weeks after final treatment versus none in the placebo group in its intention-to-treat analysis. That is a threshold response at a specified visit, not a mean change, a visible before-and-after guarantee or the fraction of all people who might seek the product.
The publication also documents substantial non-completion, different analysis populations and an ultrasound calculation based on sampled thickness and treatment area. Those details affect how the threshold result should be read. The participant-flow review tracks the randomized, treated and analyzed counts. A cross-trial chart that keeps only “69.6%” and removes the method, visit and population would manufacture comparability that the study did not establish.
Keep the threshold attached to its method
- Design: randomized, single-blind, placebo-controlled.
- Primary response: ultrasound-derived loss of at least 150 mL.
- Visit and analysis set: retain both beside the reported percentage.
The 2026 paper centered a clinician rating
The 2026 Phase 2b publication made at least one-grade improvement on the clinician-reported abdominal fat rating scale at 12-week follow-up its primary endpoint. The abstract reports 23/30 (76.7%) in the CBL-514 analysis group and 7/37 (18.9%) in placebo. Participant ratings and MRI-assessed volume were separate outcomes. A grade is ordinal; it cannot be converted into the 2025 paper’s 150 mL ultrasound threshold or the 2022 study’s mean change. MRI and ultrasound also describe measurements obtained through different procedures.
For a clean evidence table, give each paper one row with its design, primary endpoint, tool, analysis population and assessment time. Then identify the question a reader is trying to answer. If it concerns a numerical pooled effect, these three publications alone do not justify calculating one from their headline percentages. If it concerns the direction of the research program, they show changing study design and measurement choices. The MRI and scales guide explains the 2026 measures in detail.
Build a source-faithful evidence table
- 2026 primary endpoint: at least one clinician-rated grade at 12 weeks.
- 2026 quoted analysis: 23/30 versus 7/37.
- Keep MRI, ultrasound and rating scales in separate columns.
Reviewed 31 October 2026. This independent editorial page describes published evidence and research-procurement documentation. It does not provide treatment, preparation or administration advice. Verify current source versions before relying on a changing clinical or regulatory record.
Frequently asked questions
Why do CBL-514 papers quote different success percentages?
They use different study designs, endpoints, visits and analyzed groups. The 2025 primary threshold is ultrasound-derived volume; the 2026 primary endpoint is a clinician rating.
Can the 2025 and 2026 percentages be averaged?
No defensible average follows from the headline percentages alone. They measure different outcomes in different analysis populations.
Was the 2022 Phase IIa study placebo controlled?
The published Phase IIa report describes randomized allocation among active dose groups and an open-label design, not a placebo comparison.
Do trial dose levels define a research-vial specification?
No. Protocol interventions describe the sponsor’s investigated formulation. An independently sourced material needs separate identity, assay and batch evidence.